MoonLake Immunotherapeutics MLTX · SEC Filings

130

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating it...

Price12.62

Market Cap1.07 B

Float75.12 M

CountryCH

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

MoonLake Reports Q3 2026 Financial Results and Business Updates

Nov 4, 2026

8-K

MoonLake Immunotherapeutics Submits BLA to FDA for Sonelokimab in Hidradenitis Suppurativa

Sep 30, 2026

8-K

MoonLake Announces Positive Phase 3 IZAR-1 Results for Sonelokimab in Psoriatic Arthritis and Q2 2026 Financial Results

Aug 10, 2026

8-K

MoonLake Immunotherapeutics Announces Full Exercise of Underwriter Option for Additional Shares

Jul 14, 2026

8-K

MoonLake Immunotherapeutics Announces Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Jun 25, 2026

8-K

MoonLake Announces Positive Week 52 Results for Sonelokimab in Phase 3 VELA Program for Hidradenitis Suppurativa

Jun 22, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

Cormorant Asset Management, LP (Filed by)

Aug 14, 2026

SCHEDULE 13G

T. Rowe Price Investment Management, Inc. (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Deep Track Capital, LP (Filed by)

Aug 14, 2026

4

Reich Kristian (Reporting)

Jul 29, 2026

4

Reich Kristian (Reporting)

Jul 23, 2026

4

Reich Kristian (Reporting)

Jul 21, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

May 13, 2024

CORRESP

Form CORRESP - Correspondence

May 7, 2024

LETTER

Form UPLOAD - SEC-generated letter

Apr 29, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 12, 2023

CORRESP

Form CORRESP - Correspondence

Sep 7, 2023

LETTER

Form UPLOAD - SEC-generated letter

Sep 6, 2023